Current News

Contact | Print version | PDF version | Send article | RSS feed

bioMerieux Gains Critical Oncology and Theranostics Capabilities with the Acquisition of Molecular Diagnostics Company AviaraDx

15 Sep 2008 - bioMérieux has acquired the privately held AviaraDx, Inc., a molecular in vitro diagnostics company, based in San Diego, California (USA). AviaraDx’s diagnostic tests, based on their proprietary technologies, are used in the molecular classification of cancers and to assist oncologists in making critical therapeutic decisions. The company has built a molecular R&D lab and a small sales & marketing team, as well as a high complexity Clinical Laboratory Improvement Amendments (CLIA) certified service lab.
 
"The acquisition of AviaraDx is a major milestone in bioMérieux’s long-term growth strategy. Their molecular technology in tumor tissue and broad clinical capabilities will help us achieve Dr. Christophe Mérieux’s vision of providing patients with personalized, predictive medicine,” stated Stéphane Bancel, Chief Executive Officer of bioMérieux. "We are also very excited to welcome the talented AviaraDx team to bioMérieux,” he added.
 
bioMérieux acquired full ownership of AviaraDx for $60 million. The company plans to keep AviaraDx as an independent legal entity called bioTheranostics, Inc. Richard Ding, bioMérieux’s Corporate Vice President of Business Development and Theranostics, has been named Chief Executive Officer of bioTheranostics. He will also continue to serve as a member of the bioMérieux Management Committee and to lead bioMérieux’s business development and theranostics activities.